
Collaboration set to develop neuroinflammation therapeutics
Neuroscience company AndzonBio2 has announced it will collaborate with the University of Cambridge and Cambridge Enterprise to develop therapeutics for neuroinflammation. The agreement states the parties will combine AndzonBio2’s expertise in early drug development and translational strategy with Cambridge’s world-leading neuroscience capabilities. This will also include the drug discovery platform developed… Read More













